BioNTech SE BNTX was down sharply on Tuesday after issuing weaker‑than‑expected 2026 revenue guidance as Covid vaccine sales ...
BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted ...
BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...
If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current ...
BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.
BioNTech (BNTX) shares fell over 20% after the company reported an earnings miss and announced plans for its founders to ...
BioNTech’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise ...
The German biotech provides a weak full-year outlook and announces the exit of its co-founders.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results